2-Methylresorcinol
Based on 1 Customer Validation
2-Methylresorcinol is a tripyrrane analog. 2-Methylresorcinol is a cosmetic ingredient with endocrine activity. 2-Methylresorcinol combined with Butylhydroxyanisole (HY-B1066) and Avobenzone (HY-B0316) has anti-glucocorticoid-like activity. 2-Methylresorcinol combined with Avobenzone only has anti-androgen-like activity. 2-Methylresorcinol can be used as for cosmetic industry.
For research use only. We do not sell to patients.
- CAS No.: 608-25-3
- Formula: C7H8O2
- Molecular Weight:124.14
-
Storage:
RT, stored under nitrogen.
In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-W012816R
2-Methylbenzene-1,3-diol (Standard) -
HY-77490A
1,3-Butanediolβ-Hydroxybutyrate Producer -
HY-D0168
OrcinolMelanogenesis Inhibitor -
HY-B0903
Hexylene glycolSurfactant -
HY-B0986
HexylresorcinolAntimicrobial -
HY-W017378
TrimethylhydroquinoneIntermediate -
HY-W011875
2-IsopropylthioxanthonePhotoinitiator -
HY-B0903R
Hexylene glycol (Standard)Surfactant -
HY-W011816
1,2-HexadecanediolReducing Agent -
HY-W133921
Dipropylene glycolBiochemical Assay Reagents
Biological Activity
Description
Chemical Information
-
CAS No. 608-25-3
-
Appearance Solid
-
Molecular Weight 124.14
-
Formula C7H8O2
-
Color Off-white to light yellow
-
SMILES
OC1=CC=CC(O)=C1C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
RT, stored under nitrogen
In solvent -80°C 1 year -20°C 6 months
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (786 KB)
- English - EN (786 KB)
- Français - FR (786 KB)
- Deutsch - DE (786 KB)
- Norwegian - NO (786 KB)
- Español - ES (786 KB)
- Swedish - SV (786 KB)
- Italian - IT (786 KB)
- Korean - KR (786 KB)
- Portuguese - PT (786 KB)
-
Handling Instructions (2659 KB)
References
[1]. Klopcic I, et al. Endocrine Activity of AVB, 2MR, BHA, and Their Mixtures. Toxicol Sci. 2017 Mar 1;156(1):240-251. [Content Brief]
[2]. Lash TD, et al. Synthesis of a series of aromatic benziporphyrins and heteroanalogues via tripyrrane-like intermediates derived from resorcinol and 2-methylresorcinol. J Org Chem. 2011 Aug 5;76(15):6295-308. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
2-Methylresorcinol Related Classifications
HY-W012816 Related Classifications
Powered by Bioz